4th Quarter - Report
SEQIRUS for SEQIRUS
Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Pandemic All-Hazards Preparedness Act Reauthorization; federal appropriations for preparedness, biodefense, and influenza; and regulatory issues related to biodefense and influenza preparedness
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHYLLIS FROSST | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.